Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum–taxane chemotherapy in ovarian cancer
International Journal of Clinical Oncology · 2026-08 · 31 (8) · 1576-1586
DOI: 10.1007/s10147-026-03065-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 27.05.2026. Verfasst von Kosuke Yoshida und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya, 466-8550, Japan. yoshida.ko…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, BRCA2 Protein, BRCA1 Protein, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nagoya University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Germline BRCA (gBRCA) mutations and homologous recombination deficiency (HRD) are critical factors affecting treatment response; however, their association with hematologic toxicity remains controversial. This study assessed the interplay between these molecular features and hematologic adverse events during platinum–taxane chemotherapy.
Methods
We retrospectively reviewed 62 patients with stage III–IV ovarian cancer between 2022 and 2024. After excluding 8 patients, 54 patients were stratified according to gBRCA and HRD status, and hematologic adverse events were evaluated for up to six treatment cycles. Moreover, meta-analysis was performed to integrate previously published data.
Results
First, after excluding patients with uncertain gBRCA status, eight gBRCA mutation carriers were compared with 33 confirmed non-carriers. gBRCA mutation carriers tended to exhibit lower neutrophil counts during treatment; however, no statistically significant differences in hematologic toxicities were observed across treatment cycles. In the pooled meta-analysis, gBRCA mutation carriers demonstrated significantly increased odds of neutropenia (odds ratio [OR] 1.68, 95% confidence interval [CI] 1.16–2.44) and G-CSF use (OR 3.09, 95% CI 1.19–8.03), whereas no significant associations were observed for anemia, thrombocytopenia, dose delay, or dose reduction. Second, 23 HRD-positive patients and 15 HRD-negative patients were analyzed. HRD-positive patients did not demonstrate increased hematologic toxicity compared with HRD-negative patients. Although baseline hemoglobin levels were lower in HRD-positive patients, these differences preceded chemotherapy initiation.
Conclusion
This study provides real-world evidence of a modestly increased risk of neutropenia and G-CSF use in gBRCA carriers during platinum–taxane chemotherapy; however, these differences did not appear to compromise treatment delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya, 466-8550, Japan. yoshida.kousuke@med.nagoya-u.ac.jp.
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya, 466-8550, Japan.
- Department of Medical Genomics Center, Nagoya University Hospital, Nagoya, Japan.
Förderung
- Nagoya University
Zitieren
APA
Yoshida, K., Araki, H., Yamada, Y., Masahashi, Y., Miyamoto, E., Katayama, K., Kubokawa, M., Mogi, K., Yoshihara, M., Nagao, Y., Tamauchi, S., Yokoi, A., Yoshikawa, N., Niimi, K., & Kajiyama, H. (2026). Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum–taxane chemotherapy in ovarian cancer. International Journal of Clinical Oncology, 31(8), 1576-1586. https://doi.org/10.1007/s10147-026-03065-4
Vancouver
Yoshida K, Araki H, Yamada Y, Masahashi Y, Miyamoto E, Katayama K, et al. Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum–taxane chemotherapy in ovarian cancer. International Journal of Clinical Oncology. 2026;31(8):1576-1586. doi:10.1007/s10147-026-03065-4
BibTeX
@article{Yoshida2026,
author = {Yoshida, Kosuke and Araki, Hajime and Yamada, Yurika and Masahashi, Yoshiki and Miyamoto, Emiri and Katayama, Komei and Kubokawa, Mei and Mogi, Kazumasa and Yoshihara, Masato and Nagao, Yukari and Tamauchi, Satoshi and Yokoi, Akira and Yoshikawa, Nobuhisa and Niimi, Kaoru and Kajiyama, Hiroaki},
title = {Association of germline BRCA and homologous recombination deficiency with hematologic toxicity during platinum–taxane chemotherapy in ovarian cancer},
journal = {International Journal of Clinical Oncology},
year = {2026},
volume = {31},
number = {8},
pages = {1576--1586},
doi = {10.1007/s10147-026-03065-4}
}
EUVIMED